Trending Topic

abstract blue eye
8 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

On 28 May 2024, enrolment in phase III clinical trials for sozinibercept in neovascular age-related macular degeneration (nAMD) was completed.1 These trials include two large multicentre, double-masked, randomized controlled trials (RCTs): COAST (OPT-302 with aflibercept in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757636) and ShORe (OPT-302 with ranibizumab in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757610).2,3 These trials represent one of the largest phase […]

Ophthalmic World Leaders (OWL)

Ophthalmic World Leaders (OWL)
Web Address: OWL website
Ophthalmic World Leaders (OWL)

OWL was founded over 15 years ago as a 501c3 nonprofit entity.  It remains the only organization in ophthalmology to unite every stakeholder: leading practice administrators, industry executives, consultants, media, PR, and physicians. It is, inarguably, the best network in ophthalmology.

OWL is a membership organization and typically organizes several physical events a year at major ophthalmic meetings, bringing in world-class speakers. We also have several local chapters around the US, as well as providing robust online programming live and ‘on-demand’ to our members.

Vision
OWL’s vision is to promote and develop diverse leadership to advance Ophthalmic Innovation and Patient Care.

Mission
OWL works across Ophthalmology. Our mission is to provide professional and personal development and create opportunities for collaboration.

Further Resources

Close Popup